Hoffmann-la Roche Inc.

Roche Palo Alto LLC

Other

The Pennsylvania State University

F. Hoffmann-la Roche Ag

Ulrich Andreas Gubler

Maurice Kent Gately

David Howard Presky

Alvin Seth Stern

Jeffrey David Hulmes

Richard Anthony Chizzonite

Yu-Ching Eugene Pan

Frank John Podlaski

Paul Shartzer Dietrich

Steven B Mizel

Peter T Lomedico

Bruce Koch

Heather Guthrie

Anne On Chua

A stable eukaryotic cell line that expresses hERG and exhibits a stable current under electrophysiological test conditions is provided.

Stable cell lines expressing hERG

The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth. Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.

Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto

The invention relates to the cloning of the human interleukin-1&agr; gene, its engineering into suitable expression vectors, hosts transformed with such expression vectors, and production of biologically active recombinant human interleukin-1&agr;.

Recombinant human recombinant human interleukin-1&agr;

The invention relates to the cloning of the human IL-1 gene, its engineering into suitable expression vectors, transformation of host organisms with such expression vectors and production of biologically active recombinant human IL-1 by culture of such transformed cells. Additionally, the invention relates to the isolation and use of the resulting recombinant human IL-1 polypeptides.

Recombinant human interleukin-1.alpha.

A recombinant human IL-12 receptor complex produced on the surface of a non-human mammalian cell and free from other human proteins, the complex comprising the beta1 receptor protein complexed with a beta2 receptor protein, which complex is capable of binding to human IL-12 with high affinity. A recombinant human IL-12 beta2 receptor protein produced on the surface of a non-human mammalian cell, free from other human proteins, in its active form. In addition, a non-human mammalian cell having expressed on its surface the recombinant human IL-12 beta2 receptor protein or the recombinant human IL-12 receptor complex, which cell proliferates in the presence of human IL-12. A non-human mammalian cell having the human IL-12 beta2 receptor protein or the complex expressed on its surface and which proliferates in response to human IL-12 is useful for determining whether a given compound inhibits biological activity of human IL-12 or is an IL-12 agonist.

Low affinity human IL-12 beta2 receptor

Antibodies to human IL-12 beta 2 receptor protein or an IL-12 receptor complex, the complex comprising the beta1 receptor protein complexed with a beta2 receptor protein, which complex is capable of binding to human IL-12 with high affinity.

Antibodies to receptors for human interleukin-12

A recombinant human IL-12 beta2 receptor protein produced on the surface of a non-human mammalian cell, free from other human proteins, in its active form. In addition, a non-human mammalian cell having expressed on its surface the recombinant human IL-12 beta2 receptor protein, which cell proliferates in the presence of human IL-12. A non-human mammalian cell having the human IL-12 beta2 receptor protein on its surface and which proliferates in response to human IL-12 is useful for determining whether a given compound inhibits biological activity of human IL-12 or is an IL-12 agonist.

DNA encoding receptors for the beta-2 chain of human IL-12

This invention relates to substantially pure Interleukin-12 receptor cDNAs and protein and uses therefore. The Interleukin-12 receptor is shown to be a member of the cytokine receptor superfamily and has a high homology to human gp130.

Human receptor for interleukin-12

The present invention relates to antibodies which bind to a novel cytotoxic lymphocyte maturation factor. When bound to the cytotoxic lymphocyte maturation factor, the antibodies can neutralize bioactivity of the factor.

Growing community of inventors

Glen Ridge, NJ, United States of America

Ulrich Andreas Gubler